Your link failed, but I found this, but with a conclusion worded differently. Wow! 17 of 23 survived - 74% - despite 20 of the 23, or 87%, having "significant co-morbidities." And only one death - a 4% rate. I'm no expert at clinical details of these complicated trials, but this looks stellar to me. And of course, the SP is down today. I guess the news is obviously too good to be true; we all need to dump our shares before it's too late.